ABT-299

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531379

CAS#: 161395-35-3

Description: ABT-299 is a prodrug of A-85783.

Chemical Structure

img
ABT-299
CAS# 161395-35-3
Instruction

Theoretical Analysis

MedKoo Cat#: 531379
Name: ABT-299
CAS#: 161395-35-3
Chemical Formula: C32H28ClFN4O4S
Exact Mass: 618.15
Molecular Weight: 619.108
Elemental Analysis: C, 62.08; H, 4.56; Cl, 5.73; F, 3.07; N, 9.05; O, 10.34; S, 5.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ABT-299

IUPAC/Chemical Name: [3-[(3R)-7-[1-(dimethylcarbamoyl)-6-(4-fluorophenyl)indole-3-carbonyl]-1,3-dihydropyrrolo[1,2-c][1,3]thiazol-3-yl]pyridin-1-ium-1-yl]methyl acetate chloride

InChi Key: NKIONDJYXPXFFL-JSSVAETHSA-M

InChi Code: InChI=1S/C32H28FN4O4S.ClH/c1-20(38)41-19-35-13-4-5-23(16-35)31-36-14-12-26(29(36)18-42-31)30(39)27-17-37(32(40)34(2)3)28-15-22(8-11-25(27)28)21-6-9-24(33)10-7-21;/h4-17,31H,18-19H2,1-3H3;1H/q+1;/p-1/t31-;/m1./s1

SMILES Code: CC(OC[N+]1=CC=CC([C@H]2SCC3=C(C(C4=CN(C(N(C)C)=O)C5=C4C=CC(C6=CC=C(F)C=C6)=C5)=O)C=CN23)=C1)=O.[Cl-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 619.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Snapper JR, Lu W, Lefferts PL, Thabes JS. Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep. J Appl Physiol (1985). 1998 May;84(5):1610-4. PubMed PMID: 9572806.

2: Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM Jr, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists. J Med Chem. 1998 Jan 1;41(1):74-95. PubMed PMID: 9438024.

3: Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, Abellán Alemán A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010.

4: Albert DH, Magoc TJ, Menacherry SD, Morgan DW, Sun E, Reyes AE, Kleinert HD, Carter GW, Summers JB. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist. Inflamm Res. 1997 Jul;46(7):272-7. PubMed PMID: 9266276.

5: Albert DH, Luo G, Magoc TJ, Tapang P, Holms JH, Davidsen SK, Summers JB, Carter GW. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats. Shock. 1996 Aug;6(2):112-7. PubMed PMID: 8856845.

6: Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers JB, Carter GW. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. J Pharmacol Exp Ther. 1996 Jun;277(3):1595-606. PubMed PMID: 8667228.

7: Kruse-Elliott KT, Albert DH, Summers JB, Carter GW, Zimmerman JJ, Grossman JE. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock. 1996 Apr;5(4):265-73. PubMed PMID: 8721386.

8: Albert DH, Magoc TJ, Kleinert HD, Sun E, Reyes AE, Carter GW, Summers JB. Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist. Adv Exp Med Biol. 1996;416:381-7. PubMed PMID: 9131177.

9: Summers JB, Albert DH, Davidsen SK, Conway RG, Holms JH, Magoc TJ, Luo G, Tapang P, Rhein DA, Carter GW. ABT-299, a potent antagonist of platelet activating factor. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:475-7. PubMed PMID: 7732895.

10: Davidsen SK, Summers JB, Albert DH, Holms JH, Heyman HR, Magoc TJ, Conway RG, Rhein DA, Carter GW. N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist. J Med Chem. 1994 Dec 23;37(26):4423-9. PubMed PMID: 7799395.